Show: 1 day 1 week 1 month All
Custom (decided): –
Clear all
Coverage since November 3, 1994
✉️ New decisions, briefed in your inbox every morning — subscribe to Daily Case Law, free →

Federal Circuit

Federal Circuit
Uncategorized

Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. — Federal Circuit Holds Specific Dosing Method for Renally Impaired Patients Is Patent Eligible

The Federal Circuit reversed a district court’s ruling that Endo’s oxymorphone dosing patent was ineligible, holding that claims directed to a specific method of treating specific patients with specific dosages are not merely abstract natural laws.

Federal Circuit
Uncategorized

Natural Alternatives International, Inc. v. Creative Compounds, LLC — Federal Circuit Holds Beta-Alanine Supplement Patents Are Eligible as Unnatural-Quantity Treatment Claims

The Federal Circuit reversed a district court’s ruling that patents on using beta-alanine as a dietary supplement were invalid under § 101, holding that method of treatment claims covering use of a natural compound in non-naturally-occurring quantities to alter physiology are patent eligible.

Federal Circuit
Uncategorized

Athena Diagnostics v. Mayo Collaborative Services — Federal Circuit Invalidates MuSK Diagnostic Patent, Splits Sharply on § 101 Reform

The Federal Circuit invalidated a diagnostic patent for detecting autoantibodies linked to myasthenia gravis, then denied en banc rehearing in a rare decision accompanied by eight separate opinions, exposing the court’s deep division over § 101 and diagnostic patents.

Federal Circuit
Uncategorized

Trading Technologies v. IBG — Federal Circuit Finds Futures Trading Interface Patents Ineligible as Abstract Ideas

The Federal Circuit held that Trading Technologies’ patents on a graphical user interface for electronic futures trading were patent-ineligible abstract ideas under Alice — finding that displaying market data and allowing traders to place orders by clicking on a price ladder represented an abs

Federal Circuit
Uncategorized

Ancora Technologies, Inc. v. HTC America, Inc. — Federal Circuit Holds BIOS-Based Software License Verification Patent Is Eligible Under § 101

The Federal Circuit reversed a district court’s dismissal and held that a patent claiming a method of preventing computers from running unlicensed software by using the BIOS to store a license verification key is not an abstract idea—it claims a concrete improvement to computer security functionalit

Federal Circuit
Uncategorized

Interval Licensing v. AOL — Federal Circuit Invalidates “Attention Manager” Display Patent as Claiming a Desired Result Without a Technical Solution

The Federal Circuit held that a patent covering an “attention manager” that displays content in unused screen space is ineligible under § 101, because it claims a desired outcome — non-interfering display of two information sets — without specifying any technical means of achieving it.

Scroll to Top